ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1355

Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials

Marina Magrey1, James Cheng-Chung WEI2, Arne Yndestad3, Andrew Bushmakin4, Joseph Cappelleri4, Oluwaseyi Dina5 and Atul Deodhar6, 1Case Western Reserve University, University Hospitals, Richfield, OH, 2Chung Shan Medical University Hospital, Taichung, Taiwan, 3Pfizer Inc, Oslo, Norway, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY, 6Oregon Health & Science University, Portland, OR, USA, Portland, OR

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Disease Activity, pain, Patient reported outcomes, work

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients (pts) with AS often experience impaired work productivity.1 In pts with AS receiving tofacitinib (oral Janus kinase inhibitor), improvements were observed in work productivity, activity impairment, and other patient-reported outcomes (PROs) 2,3; however, the relationships between these have not yet been quantified. This post hoc analysis examined these relationships in pts with AS.

Methods: Data were pooled from two placebo (PBO)-controlled, double-blind studies in pts with active AS receiving tofacitinib 2, 5, or 10 mg twice daily or PBO (Phase [P]2: NCT017866683; P3: NCT035026162). In the trials, work performance was evaluated by the Work Productivity and Activity Impairment Questionnaire in Spondyloarthritis (WPAI-AS). A repeated measures model assessed relationships between select PROs (AS Quality of Life [ASQoL], Pt Global Assessment of Disease [PtGA], pt assessment of total back pain and nocturnal spinal pain, and EuroQol-5-Dimension 3-Level [EQ-5D-3L] and EQ-5D-Visual Analog Scale [EQ-5D-VAS]) as predictors (anchors), and WPAI-AS domains (absenteeism, presenteeism, activity impairment, and productivity loss) as outcomes at baseline and Week (W)12/W16 (P3 study only), using the anchors as continuous variables; imposing a linear relationship between anchor and outcome. Available data from all treatment groups and time points were pooled. Incremental change analysis quantified the change of the WPAI-AS domains associated with 1 point (ASQoL, PtGA, total back pain, nocturnal spinal pain), 0.1 point (EQ-5D-3L), or 10 point (EQ-5D-VAS) change in PROs. Sensitivity analyses were performed using the anchors as categorical variables (no functional relationship imposed).

Results: Data from 330–475 pts were available, depending on the analysis. Approximately linear relationships were observed between PROs and WPAI-AS domains (Fig 1). Worst PRO scores were associated with a decline in pts’ work capacity (measured by presenteeism, productivity loss, and activity impairment [ > 65%]); best PRO scores were associated with improvements in WPAI-AS domains (8–23%) (Fig 1). Relationships between PROs and absenteeism were the weakest owing to absenteeism being low (Fig 1). Incremental worsening in PROs resulted in increased absenteeism, activity impairment, presenteeism, and productivity loss; incremental improvement in EQ-5D-3L and EQ-5D-VAS resulted in decreases in the WPAI-AS domain scores (Table). Sensitivity analysis confirmed the results of the models (Fig 2; same pattern observed for all WPAI-AS domains).

Conclusion: Evidence for linear relationships between PROs and WPAI-AS domains was observed; these were weakest for absenteeism. Interventions that control disease activity and pain are therefore likely to improve work productivity and reduce activity impairment in pts with AS.

1. Nikiphorou & Ramiro. Curr Rheumatol Rep 2020; 22: 55
2. Deodhar et al. Ann Rheum Dis 2021; 80: 1004–13
3. van der Heijde et al. Ann Rheum Dis 2017; 76: 1340–7

Study sponsored by Pfizer. Medical writing support was provided by C Zauchenberger, CMC Connect, and funded by Pfizer.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Magrey, AbbVie, Eli Lilly, Novartis, Pfizer Inc, UCB; J. WEI, AbbVie, Bristol-Myers Squibb, Amgen, Celgene, Chugai, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis, TSH Taiwan, UCB, JHL Taiwan; A. Yndestad, Pfizer Inc; A. Bushmakin, Pfizer; J. Cappelleri, Pfizer; O. Dina, Pfizer; A. Deodhar, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, UCB Pharma, Aurinia, Moonlake.

To cite this abstract in AMA style:

Magrey M, WEI J, Yndestad A, Bushmakin A, Cappelleri J, Dina O, Deodhar A. Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/relationships-between-work-productivity-activity-impairment-and-select-patient-reported-outcomes-in-patients-with-ankylosing-spondylitis-a-post-hoc-analysis-of-two-placebo-controlled-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationships-between-work-productivity-activity-impairment-and-select-patient-reported-outcomes-in-patients-with-ankylosing-spondylitis-a-post-hoc-analysis-of-two-placebo-controlled-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology